Repare Therapeutics Inc

Repare Therapeutics Inc. is a clinical-stage precision oncology company that discovers and develops therapeutics in Switzerland and the United States. It uses its proprietary genome-wide, CRISPR-enabled SNIPRx platform to develop cancer therapies targeting genomic instability mechanisms, including DNA damage repair. Its pipeline includes camonsertib (RP-3500), an oral small molecule inhibitor of Ataxia-Telangiectasia and Rad3-related protein kinase in Phase 1/2 trials for solid tumors; lunresertib (RP-6306), an oral small molecule inhibitor of Protein Kinase Membrane-associated tyrosine- and threonine-specific cdc-2 inhibitory kinase in Phase 1/2 trials; RP-1664, an oral PLK4 inhibitor in Phase 1 trials; and RP-3467, an inhibitor of adenosinetriphosphatase activity on the helicase domain of DNA polymerase theta in Phase 1 trials. The company has strategic collaborations with Hoffmann-La Roche Inc., F. Hoffmann-La Roche Ltd, Debiopharm International S.A., Bristol-Myers Squibb Company, Ono Pharmaceutical Company Ltd., and New York University. Incorporated in 2016 and headquartered in Montreal, Canada, it became a subsidiary of Xenotherapeutics Inc. as of January 28, 2026.